Clinical Trials
22 trialsNCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00003614 2023-06-15
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02866955 2020-03-09
EFESE
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT00165399 2018-06-25
Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00005810 2016-07-14
Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00016913 2016-07-06
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00052845 2016-07-01
Docetaxel, Estramustine, and Exisulind in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00003584 2016-05-12
Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer
University of New Mexico
Phase 2 Completed
NCT00151073 2015-01-22
Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00151060 2015-01-21
Estramustine, Etoposide and Paclitaxel Treatment for Hormonally Responsive Adenocarcinoma of the Prostate
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00183924 2014-05-22
Estramustine, Docetaxel, and Carboplatin for Patients With Hormone Refractory Prostate Cancer Progressing After Mitoxantrone-Based Chemotherapy.
University of Southern California
Phase 2 Completed
NCT01250717 2014-02-04
Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00028769 2013-07-16
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00021372 2013-07-10
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fox Chase Cancer Center
Phase 2 Completed
NCT00016107 2013-06-05
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00046826 2013-04-04
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00014352 2013-01-16
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00003084 2012-07-30
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00083005 2012-03-15
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00193271 2011-05-03
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00193193 2010-08-04
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00541281 2009-10-27
Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Completed